initi price target
pama pullback short live management execut support valuat
unfortun miss massiv run share
degre multipl expans greater
anticip heel solid execut growth uptick
thing start turn bore manag would consist
over-deliv everi shock industri much deeper
anticip cut stunt momentum continu struggl
math use deriv magnitud cfl haircut
nonetheless current realiti share ep adjust
downward thank manag execut remain construct
notabl up-tick outreach activ well strong cost
manag help cushion unforeseen blow
degre activ hold key ep compound-annual-growth-rate san tax reform
forecast contempl degre transact activ remain
elev yield slightli st estim revenu ep
match low end management guidanc rang coupl
upsid associ tax reform signific instanc
nice tailwind fundament stori howev total tsr still
project hsd competit return argu valuat
alreadi somewhat reflect realiti thu like
see notabl upsid share event pama repriev
plausibl event strateg option given bia
toward vertic integr given dynam see risk reward
balanc thu initi share rate
thing watch revisit pama pace outreach
debat big headwind pama prove
manag back away lt target dx servic
 tech supplement core growth omx left post realiz
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt translat
ebitda vs average price-to-earnings basi
translat vs average
downsid risk challeng associ integr small
outreach lab deal could depress return invest capit prove
distract recent vertic integr hc servic organ lead
increas price pressur given heighten focu unit cost
potenti pama relat price cut bleed commerci
price ultim lead neg margin cycl
upsid risk pama repriev lead ep upward revis
remov key growth overhang allow resumpt pe
expans open contract favor econom allow
lh reap benefit expans small player
pressur small lab lead materi up-tick activ highli
attract price allow notabl b/ deploy
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi pt
last page report import disclosur regard stock report
tabl content
debat big headwind pama prove
debat manag back away lt target
debat omx left post realiz invigor save
financi model pama push ep end lt
point differenti vs st
iv valuat risk tax reform vs pama hit
 conclus initi market effici
major turnaround creat signific valu servic
o/pd turnaround fell pama
provid clinic laboratori test across us
help diagnos monitor diseas well hit life
thesi pama took bite acceler growth path
share fairli valu hsd total return profil
well upsid benefit tax reform
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk pama relat price hit bleed
commerci book lead perpetu margin pressur
clinic lab test provid almost revenu
ceo rusckowski led impress growth recoveri
previous cfo hill-rom
previous labcorp
previous chief healthcar offic heathtap
previous manag director pwc
debat big headwind pama prove
outcom surpris given mani lab includ
pama result sizeabl hw pre offset
pama controversi start cmss desir
cmss decis guid price hit
conduct market-bas survey lab price
hit
lab servic one area
govern pay above-market price
waffl whether includ hospit outreach
lab market much higher rate
septemb announc hospit lab
would includ rate calcul
mean lh repres disproportion
calcul result overal much lower
pama lower ep compound-annual-growth-rate bottom end lt rang
pama rollback possibl uptick like
analyst day laid long-
revenu growth includ
earn growth revenu growth m-hsd
price cut probabl realiz
somewhat unusu issu multi-year price
possibl agenc revisit pama
provid relief futur year
dgx/lh independ lab
market mani smaller competitor higher
cost structur therefor like
hurt pama
smaller lab alreadi
pama estim
bar pama repriev like see small
lab sale correspond decreas price paid
pama unpleas manag potenti disastr small lab
revenu impact total drop downtax affect hit januari
debat manag back away lt target
keep ep growth m-hsd rang
 may add ep growth
discuss prior slide manag issu
lt guidanc prior pama final decis regard
get estim
 boost revenu growth
repo provid ep growth per year
execut execut execut see thru pama
although pama creat notabl headwind
end day headwind manag
low end lt guidanc rang feasibl
remain activ front
volum growth key difficult
off-set entireti price cut cost see key
ultim situat play come
execut potenti pama relief
pama damag small independ lab
much appear
low-end long-term guidanc rang still appear feasibl
improv hospit strategi open bn market
reduc payer leakag drove addl rev
focu sale team sr relationship
refer test advanc test
acquire/partn outreach lab busi
profession laboratori servic
estim
inpati could
contribut like platform
also continu invest technolog
safeway partner open patient
servic center safeway supermarket
provid conveni locat patient
current store
jv open patient servic center
expand basic healthcar servic
help gain cost leverag
datadiagnost allow provid pull
real-tim patient report fill
miss part medic histori data
qualiti score report
manag prescrib modul
combin sequenc tumor analysi
highlight mutat respond target
therapi clinic trial
document data manag
intellitest manag current info test info
li liais intern lab interfac
assert expand supplement area
debat omx left post realiz invigor save
increas focu opex pama cut bite
howev cost cut wont necessarili translat omx
given pama pressur see om like stabl
manag disciplin regard
cost invigor otherwis unabl
fulli realiz benefit given
pama price cut cost cut mere off-set
need invest continu growth acceler
need continu invest technolog
given invest see margin ultim
stabl see right longer term unless see
repriev pama
line tax reform pay pama
management expect vast major go investor
round cost save defens offens given pama flattish om
model summari point differenti vs street
swing factor pama repriev upsiz cost save pace outreach
point differenti
upsid
om flattish cost cut
help off-set pama hit
up-tick outreach
captur multipl
pama took bite acceler ep thesi solid execut save lt guid
million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount januari
valuat reflect tax upsid w/ pama relief need expans
upwardli trend nearli year metric like stagnat due induc slowdown
risk point balanc risk reward profil heighten price pressur vs pama repriev tax reform
challeng associ integr small outreach lab deal could depress return invest capit prove distract
recent vertic integr hc servic organ lead increas price pressur given heighten focu unit cost
potenti pama relat price cut bleed commerci price ultim lead neg margin cycl
pama repriev lead ep upward revis remov key growth overhang allow resumpt pe expans
open contract favor econom allow lh reap benefit expans small player
pressur small lab lead materi up-tick activ highli attract price allow notabl b/ deploy
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs pre tax reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi pt upsid
acceler growth stunt pama w/ solid execut tax reform enough bia valuat upward
unfortun miss massiv run share degre
multipl expans greater anticip heel solid execut growth uptick
thing start turn bore manag would consist over-deliv
everi shock industri much deeper anticip cut stunt momentum
continu struggl math use deriv magnitud cfl
haircut nonetheless current realiti share ep adjust downward
thank manag execut remain construct notabl up-tick outreach
activ well strong cost manag help cushion unforeseen blow
forecast contempl degre transact activ remain elev yield slightli
st estim revenu ep match low end management guidanc rang
coupl upsid associ tax reform signific instanc
nice tailwind fundament stori howev total tsr still project hsd
competit return argu valuat alreadi somewhat reflect realiti
thu like see notabl upsid share event pama repriev
plausibl event strateg option given bia toward vertic integr
given dynam see risk reward balanc thu initi share rate
thing watch revisit pama pace outreach omx trajectori
pleas feel free reach question follow-up
medic suppli devic
valuat price target base dcf methodolog contempl wacc termin ebitda
multipl equat perpetu growth rate pt translat ebitda vs average
downsid risk challeng associ integr small outreach lab deal could depress return invest capit
prove distract recent vertic integr hc servic organ lead increas price pressur given heighten
focu unit cost potenti pama relat price cut bleed commerci price ultim lead neg
upsid risk pama repriev lead ep upward revis remov key growth overhang allow resumpt
pe expans open contract favor econom allow lh reap benefit expans small
player pressur small lab lead materi up-tick activ highli attract price allow notabl b/
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
